ArticleScientific reports2019
Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Association of a five-metabolite and early-symptom profile with Parkinson's disease and its clinical progression.Scientific reports · 2026Article
- Acute Effects of Four Major Trace Amines on Zebrafish Behavioral, Neurochemical, and Neuroendocrine Responses.Journal of neurochemistry · 2025Article
- Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Identification of metabolites reproducibly associated with Parkinson's Disease via meta-analysis and computational modelling.NPJ Parkinson's disease · 2024Article
- Application of Synephrine to Grape Increases Anthocyanin via Production of Hydrogen Peroxide, Not Phytohormones.International journal of molecular sciences · 2024Article
- Article
- Omics data integration suggests a potential idiopathic Parkinson's disease signature.Communications biology · 2023Article
- Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.NPJ Parkinson's disease · 2022Article
- The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease.Frontiers in aging neuroscience · 2022Review
- Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.International journal of molecular sciences · 2021Review
- ASL expression in ALDH1A1Human genetics · 2021Article
- Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease.Nature communications · 2021Article
- Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases.Frontiers in neurology · 2021Review
- p-Synephrine, ephedrine, p-octopamine and m-synephrine: Comparative mechanistic, physiological and pharmacological properties.Phytotherapy research : PTR · 2020Review
- Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.Diagnostics (Basel, Switzerland) · 2020Review
- Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1).Cellular and molecular neurobiology · 2020Review
- Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective.Frontiers in neurology · 2020Review
- L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.International journal of molecular sciences · 2019Review
- Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease.Journal of Parkinson's disease · 2019Review
- Clinical Profiles of Selected Biomarkers Identifying Infection and Cancer Patients: A Gorzów Hospital Example.Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of Parkinson's disease (PD) remains a challenge to date. New evidence highlights the potential clinical value of circulating trace amines (TAs) in early-stage PD and their involvement in disease progression. A new ultra performance chromatography mass spectrometry (UPLC-MS/MS) method was developed to quantify plasmatic TAs, and the catecholamines and indolamines pertaining to the same biochemical pathways. Three groups of subjects were recruited: 21 de novo, drug untreated, PD patients, 27 in treatment PD patients and 10 healthy subjects as controls. Multivariate and univariate data analyses were applied to reveal metabolic changes among the groups in attempt to discover new putative markers for early PD detection and disease progression. Different circulating levels of tyrosine (p = 0.002), tyramine (p < 0.001), synephrine (p = 0.015), norepinephrine (p = 0.012), metanephrine (p = 0.001), β-phenylethylamine (p = 0.001) and serotonin (p = 0.006) were found among the three groups. While tyramine behaves as a putative biomarker for early-stage PD (AUC = 0.90) tyramine, norepinephrine, and tyrosine appear to act as biomarkers of disease progression (AUC > 0.75). The findings of this pilot cross-sectional study suggest that biochemical anomalies of the aminergic and indolic neurotransmitters occur in PD patients. Compounds within the TAs family may constitute putative markers for early stage detection and progression of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.